Practical considerations
Support for Optune users
Clinical Evidence
How Optune works
Optune key points
Intended use
What does it do?
What is Optune?
FIND OUT MORE ABOUT OPTUNE
Learn how Optune works, its benefits and the clinical evidence supporting its use in cancer treatment
FIND OUT MORE ABOUT OPTUNE
Optune is a portable, wearable device that uses Tumor Treating Fields (TTF) technology to treat specific types of cancer.
It is designed for convenience, allowing patients to wear it throughout their daily lives, offering a non-invasive treatment option that can support their overall treatment plan.
It is normally used alongside other anti-cancer treatments (such as chemotherapy or immunotherapy)
Optune is the trade name for the device that delivers Tumour-Treating Fields
WHAT IS OPTUNE?
Optune delivers low-intensity, alternating electric fields to the tumour. These fields interfere with the division of cancer cells, helping to slow the progression of the disease. The best evidence in in people with glioblastoma multiforme (GBM), although there is developing data in patients with brain metastases, lung cancer and mesothelioma
WHAT DOES IT DO?
Optune is typically used as an adjuvant treatment, meaning it is used alongside other therapies such as chemotherapy, surgery, or radiation.
The exact combination and timing varies between different cancers, but in patients with GBM is started a few weeks after completing chemo-radiotherapy and is worn continuously until clear disease progression is evident, while in patients with lung cancer it may be used from the start of chemotherapy
INTENDED USE
Optune is one of the few new treatments with clinical evidence supporting its effectiveness. The randomised phase 3 EF-14 trial demonstrated a survival benefit in newly diagnosed GBM patients who used Optune in addition to standard treatments (surgery, radiotherapy, and chemotherapy). These patients had longer survival compared to those who received only standard treatment.
For patients whose disease has recurred (relapsed), Optune has shown to be as effective as chemotherapy, with many patients opting to combine both treatments for potentially better outcomes.
Optune has also shown promise in treating other cancers, including lung and pancreatic cancers, where it has been shown to improve survival rates when used in conjunction with immunotherapy or other treatments.
CLINICAL EVIDENCE
New treatment approach: Optune uses alternating electric fields to disrupt the division of cancer cells, particularly effective in rapidly proliferating cells like those in glioblastoma (GBM).
Clinical evidence: The EF-14 trial showed that Optune, when combined with standard treatment, led to a significant survival advantage for newly diagnosed GBM patients. For recurrent disease, Optune is as effective as chemotherapy and can be used in combination with it.
Emerging use in other cancers: There is emerging evidence suggesting that Optune can also improve outcomes in lung and ovarian cancers.
Inconvenience: While using Optune requires some learning and adaptation, is is feasible. We have many patients who have used Optune for several years, with excellent weartime throughout that time
Optune key points
Optune uses self-adhesive electrode pads applied to the body near the tumour. These pads are connected to a portable device that generates alternating electric fields. Patients are encouraged to wear the device for at least 18 hours a day. Research suggests that longer usage may increase the benefits, particularly for GBM patients.
For patients with brain tumours, the pads are placed on the scalp, and so the patient's head needs to be kept shaved (patients re-shave every 2- 4 days).
For patients with other cancers (lung, pancreas) the pads are applied to the relevant body part (chest, abdomen)
HOW OPTUNE WORKS
Inconvenience: Using Optune requires significant lifestyle adjustments. Patients must wear the device for extended periods, keep their scalp shaved (for brain tumour treatments), and regularly change electrodes. However, we know hoe to support patients through this process, and we have many patients who have managed to use Optune for several years.
Cost: The cost of Optune can be substantial, often exceeding £17,000 per month for self-paying patients. While financial assistance programs may be available, eligibility and support vary. Some UK health insurance companies may cover the costs, but this is not universal.
PRACTICAL CONSIDERATIONS
SUPPORT FOR OPTUNE USERS
To help with the challenges associated with using Optune, comprehensive support is essential, including:
- Device Support Specialist: Optune provides a dedicated specialist who supports patients with device setup, training, and ongoing guidance. They can visit patients in their homes to assist.
- Patient Communities: Online support groups and email lists connect patients with others who use Optune, offering a space to share experiences, advice, and coping strategies.
- Professional Support: A growing group of clinicians is becoming more familiar with Optune, including how to manage side effects and incorporate the device into a patient's treatment routine.
